- Spain CIMA (Spanish): search for “bemiparin” (external search; text not reproduced)
External search; text not reproduced. Check the Philippine package insert in the products table.
Contraindications
- Current or past immune heparin-induced thrombocytopenia
- Disseminated intravascular coagulation due to heparin-induced thrombocytopenia
- Active bleeding or bleeding disorders
- Severe hepatic or pancreatic disease
- Central nervous system, eye or ear surgery or injury within 2 months
- Bacterial endocarditis
- Lesions prone to bleed (active ulcer, hemorrhagic stroke, aneurysm, brain tumor)
- Regional anesthesia at treatment doses
- Hypersensitivity to heparins or pork products
Dosing: Adult
- Treatment of deep vein thrombosis with or without pulmonary embolism: 115 IU anti-Xa/kg SC once daily for 7 ± 2 days (under 50 kg: 5,000 IU; 50–70 kg: 7,500 IU; 70–100 kg: 10,000 IU; 100–120 kg: 12,500 IU)
- DVT with transient risk factors, when oral anticoagulation is contraindicated or unsuitable: 3,500 IU SC once daily, up to 3 months
Dosing: Altered kidney function
Bemiparin is a low-molecular-weight heparin whose anti-Xa exposure is significantly higher at creatinine clearance (CrCl) below 30 mL/min. The Spanish label needs no change at CrCl 30–80 (with clinical monitoring) and reduces the treatment dose to 75% (about 85 IU/kg once daily) below 30, with anti-Xa monitoring. It has no US FDA label.
Kidney function measure: Spanish summary of product characteristics (ficha técnica) uses creatinine clearance (CrCl, mL/min).
Show full dosing details
- CrCl ≥60 mL/min
- Treatment of DVT: 115 IU anti-Xa/kg SC once daily for 7 ± 2 days (weight bands 5,000 to 12,500 IU) (ficha técnica).
- CrCl 30–59 mL/min
- CrCl 30–80: no dose adjustment; careful clinical monitoring (ficha técnica).
- CrCl 15–29 mL/min
- CrCl <30: exposure rises. After weighing bleeding and thrombosis risk, use 75% of the treatment dose (about 85 IU anti-Xa/kg once daily) in acute DVT; monitor closely and consider anti-Xa about 4 hours after a dose (ficha técnica).
- CrCl <15 mL/min (not on dialysis)
- CrCl <30: exposure rises. After weighing bleeding and thrombosis risk, use 75% of the treatment dose (about 85 IU anti-Xa/kg once daily) in acute DVT; monitor closely and consider anti-Xa about 4 hours after a dose (ficha técnica). No data below CrCl 15; unfractionated heparin is generally preferred.
- Hemodialysis (intermittent)
- Not studied (no hemodialysis-circuit or treatment dose for dialysis in the ficha técnica). Avoid; unfractionated heparin is preferred, with specialist input.
- Peritoneal dialysis
- Not addressed; if used, as CrCl <30 with anti-Xa monitoring.
- CRRT
- Not addressed.
- Dialyzable? Not stated.
- Monitoring Platelets on day 1, every 3 to 4 days and at the end of treatment (heparin-induced thrombocytopenia). Potassium before and during treatment in at-risk patients (kidney failure, diabetes), especially beyond 7 days. Anti-Xa at CrCl <30. Neuraxial anesthesia timing (ficha técnica 4.4).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: AEMPS (Spain) product information (May 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not recommended under 18 years (ficha técnica).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Solution for injection: 2,500 IU anti-Factor Xa/0.2 mL, 3,500 IU anti-Factor Xa/0.2 mL, 5,000 IU anti-Factor Xa/0.2 mL, 7,500 IU anti-Factor Xa/0.3 mL, 10,000 IU anti-Factor Xa/0.4 mL
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Bemiparin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
HiborBemiparin sodium | 10,000 IU anti-Factor Xa/0.4 mL Solution for Injection (SC)0.5 mL (Net content: 0.4mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's) | Rx | Rovi Pharma Industrial Services, S.ASpain | STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A | BRP-012 | Oct 8, 2029 | |
HiborBemiparin sodium | 2,500IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5mL (Net content: 0.2mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2 AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's) | Rx | Rovi Pharma Industrial Services, S.ASpain | STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A | BRP-008 | Oct 8, 2029 | |
HiborBemiparin sodium | 3,500 IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5 mL (Net content: 0.2 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's) | Rx | Rovi Pharma Industrial Services, S.ASpain | STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A | BRP-009 | Oct 8, 2029 | |
HiborBemiparin sodium | 5,000 IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5 mL (Net content: 0.2 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's) | Rx | Rovi Pharma Industrial Services, S.ASpain | STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A | BRP-010 | Oct 8, 2029 | |
HiborBemiparin sodium | 7,500 IU anti-Factor Xa/0.3 mL Solution for Injection (SC)0.5 mL (Net content: 0.3 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's) | Rx | Rovi Pharma Industrial Services, S.ASpain | STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A | BRP-011 | Oct 8, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Other anticoagulants, aspirin and other antiplatelets, NSAIDs, systemic corticosteroids, dextran | Avoid | More bleeding. | Not recommended. |
| Drugs that raise potassium | Adjust or monitor | Hyperkalemia. | Only under close supervision. |
| Intravenous nitroglycerin | Minor | May reduce effect. | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Bruising and hematoma at the injection site
- Mild transient thrombocytopenia (type I)
- Raised transaminases
Serious
- Major bleeding
- Heparin-induced thrombocytopenia (type II)
- Spinal or epidural hematoma with neuraxial anesthesia
- Hyperkalemia (hypoaldosteronism)
- Skin necrosis
Monitoring parameters
- Platelets on day 1, every 3 to 4 days and at the end of treatment (heparin-induced thrombocytopenia). Potassium before and during treatment in at-risk patients (kidney failure, diabetes), especially beyond 7 days. Anti-Xa at CrCl <30. Neuraxial anesthesia timing (ficha técnica 4.4). Kidney
- Platelets
- Potassium
- Anti-Xa at CrCl <30
Pharmacokinetics
Key PK parameters
| Bioavailability | About 96% (SC) |
|---|---|
| Time to peak | 2 to 3 hours (prophylactic), 3 to 4 hours (treatment doses) |
| Half-life | About 5 to 6 hours |
| Half-life in kidney failure (ESKD) kidney | Anti-Xa exposure significantly higher at CrCl <30 (not quantified) |
| Renal excretion kidney | Not stated (human) |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Agencia Española de Medicamentos y Productos Sanitarios. Hibor 7,500 IU ficha técnica (CIMA 64165) [AEMPS (Spain) product information, May 2023; no US FDA label]. https://cima.aemps.es/cima/dochtml/ft/64165/FT_64165.html
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Laboratorios Farmacéuticos ROVI, S.A. (2023). Hibor 7,500 IU anti-Xa/0.3 mL solución inyectable en jeringas precargadas (bemiparin sodium) [Ficha técnica; text revised May 2023]. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA registration 64165. https://cima.aemps.es/cima/dochtml/ft/64165/FT_64165.html
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .